Device, apparatus, and method of adipose tissue treatment

Information

  • Patent Grant
  • 8936593
  • Patent Number
    8,936,593
  • Date Filed
    Monday, September 30, 2013
    11 years ago
  • Date Issued
    Tuesday, January 20, 2015
    9 years ago
Abstract
An improved procedure for performing liposuction is obtained by utilizing a needle that includes a laser source conductor with one end of the needle being configured for insertion into a target adipose skin volume and the other end being coupled to a laser source. The needle may include one or more channels for extracting the treated adipose area. A vacuum source can be used in the extraction of the treated adipose. Further, the first end of the needle may include a cap or end-piece that reduces the build up of carbon deposits. A temperature sensor may be used as input to adjust the laser power and prevent over exposure.
Description
BACKGROUND

The present device, apparatus, and method relate to the field of adipose tissue treatment and aesthetic body sculpturing.


Liposuction is a technique for removal of fat tissue from different sites in a particular human body. The process changes the external contours of the body and sometimes is described as body sculpturing. The fat is removed by a suction device via a cannula, or a small flexible tube inserted into a body cavity for draining off fluid or introducing medication, inserted into the appropriate site in the body. The process is painful and sometimes causes excessive bleeding.


Recently, liposuction procedures have been improved by the use of infrared laser radiation delivered through a fiber inserted into a cannula and introduced into the treated tissue site. Laser radiation liquefies the adipose tissue. The liquefied tissue is then removed by suction or may be left in the body, where it gradually dissipates. Laser assisted liposuction is considered to be a more advanced and minimally invasive procedure when compared to traditional liposuction techniques.


High temperature developed at the tip of the fiber causes frequent fiber tip carbonization, forcing the treatment provider to remove the fiber, clean the carbonized end or cleave the end and insert it back into the cannula for continued treatment. The cannula with the fiber also has to be removed for liquefied tissue suction performed through the same skin port. The fiber and the cannula have to be sterilized between the different processes and patients. Alternatively, a new sterile fiber and cannula would have to be used. All of the above restrictions have the effect of slowing down the process, increasing the treated subject discomfort and increasing the cost of the treatment.


Thus, there is a need in the art and the related industries for a suitable solution to these and other existing problems.


BRIEF SUMMARY

A variety of embodiments may be provided to achieve an improved technique to conduct liposuction of a target adipose tissue volume. For instance, one embodiment includes a needle with an inner core for conducting laser energy, with one end being configured for insertion into the target volume and the other end being coupleable to a laser source. The needle is inserted into the target volume of adipose tissue and at least one laser source connected to needle irradiates the target volume of the adipose tissue and melts the tissue. In some embodiments, two or more laser sources may be utilized with at least one laser source operating in a continuous operation mode and at least one laser source operating in a pulse operation mode. In such an embodiment, the laser operating in the continuous operation mode (CW) heats up the adipose tissue and the laser source operating in the pulse mode induces mechanical stress on the adipose tissue.


In some embodiments, a temperature probe may be utilized to monitor the temperature of the target volume of the adipose tissue and provide feedback to the laser source. Advantageously, this aspect results in allowing the at least one laser source to be adjusted avoid excessive damage to the target volume of adipose tissue.


These and other embodiments will be more fully appreciated by reviewing the detailed description and the related figures.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING

The disclosure is provided by way of non-limiting examples only, with reference to the accompanying drawings, wherein:



FIG. 1 is a schematic illustration of the first exemplary embodiment of a disposable laser radiation conveying needle.



FIG. 2 is a schematic illustration of a cross section of the needle of FIG. 1.



FIGS. 3A and 3B are schematic illustrations of additional exemplary needle cross sections.



FIG. 4 is a schematic illustration of the second exemplary embodiment of a disposable laser radiation conveying needle with a carbonization resisting tip.



FIG. 5 is a schematic illustration of an exemplary embodiment of the apparatus for laser assisted liposuction employing the present needle.



FIGS. 6A-6C are schematic illustrations of the third exemplary embodiment of a disposable laser radiation conveying needle with liquefied fat removal channels.



FIG. 7 is a schematic illustration of an apparatus and method of tissue treatment employing the present disposable laser radiation conveying needle.



FIG. 8 is a schematic illustration of the forth exemplary embodiment of a disposable laser radiation conveying needle.



FIG. 9 is a schematic illustration of an additional exemplary embodiment of an apparatus for laser assisted liposuction employing the present needle.





DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

The principles and execution of the device, apparatus, and method described herein may be understood with reference to the drawings, wherein like reference numerals denote like elements through the several views and the accompanying description of non-limiting, exemplary embodiments.


The term “needle,” as used in the text of the present disclosure, means a flexible or rigid light guide configured to be inserted into the subject tissue to deliver laser radiation to a target volume of adipose tissue. In certain embodiments, the needle can be configured to withdraw liquid from the target volume in addition to the above stated uses.


The term adipose is known to those skilled in the art, and one non-limiting definition, provided for convenience only includes fatty skin tissue, or skin tissue consisting of, resembling, or relating to fat. Adipose tissue is a type of connective tissue consisting of adipose cells, which are specialized to produce and store large fat globules. These globules are composed mainly of glycerol esters of oleic, palmitic, and stearic acids.


Reference is made to FIG. 1, which is a schematic illustration of the first exemplary embodiment of a disposable laser radiation conveying needle. Needle 100 is practically a needle shaped solid or hollow light conducting body 104 having a first end 108 and a second end 112 (In the context of the present disclosure “light” and “laser radiation” have the same meaning.). The first end 108 of needle 100 can be shaped for piercing and penetrating the skin of a subject (not shown) and the second end 112 of the needle 100, depending on the length of the needle 100, is adapted to connect directly to a source of laser radiation by means of fiber optics type connector 116 or with the help of an additional interim cable. The length of needle 100 may vary from a few millimeters to a few hundred millimeters and depends on the type of treatment required or being performed. The connection to the source of laser radiation may be performed by any type of fiber optics or similar type connectors. Line 118 designates the optical axis of needle 100.



FIG. 2 is a cross section view of needle 100 taken at line I-I of FIG. 1, and is shown to have a round cross section. Needle 100 includes a solid light conducting core 120, a cladding 124 having a refractive index lower than core 120, and a protective jacket 128 that protects the sensitive fiber and provides the necessary stiffness to the needle 100. In some embodiments, as best shown in FIGS. 3B and 3C, a jacket 132 may have an elliptical shape (FIG. 3B) or the jacket 136 may have a polygonal (FIG. 3C) cross section. The diameter of core 120 can vary but operable embodiments may be 100 micron to 1500 micron, in some embodiments the diameter of cladding 124 may range from 200 micron to 2500 micron and the size of jacket 128, 132, and 136 may be 500 micron to 3000 micron or even more. Connection of needle body 104 to connector 116 may be performed by crimping, epoxy glue, or any other well known means that is established in the fiber optics industry.


First end 108 of needle 100 may be shaped for piercing the skin of a subject and may be terminated by a plane perpendicular to the optical axis 118 or oriented at an angle to the optical axis 118 of needle 100. Alternatively, end 108 may have a radius or an obtuse angle. In such case, a skin incision is made by any well known surgical means and the needle is introduced into the tissue through the skin incision. Other needle end 108 shapes that improve either skin penetration properties or laser power delivery quality are also possible and anticipated by various embodiments.


In an alternative embodiment, laser radiation emitted through the end of needle 100, assists needle 100 into the skin penetration process by providing a skin incision suitable for continuous or pulsed laser power. Such laser-performed incision may be advantageous in some aspects because it is accompanied by a simultaneous haemostatic effect, which coagulates the blood, reduces patient bleeding and shortens the recovery period.


In a second exemplary embodiment of a disposable laser radiation conveying needle shown in FIG. 4, the first end 108 of needle 100 is terminated by a sapphire, YAG (Yttrium Aluminum Garnett), or diamond plate 140, or coating. During use, certain materials resulting from interaction of the tissue with high laser power, deposit on end 108 of needle 100. These carbonized deposits increase laser light absorption at the end 108 of needle 100 and this deposit should be periodically removed. Strong laser power absorption in carbonized deposit can increase local temperature at the end 108 resulting in needle damage. Sapphire, YAG, and diamond or other similar material are generally resistant to high temperature and their use as a termination of the first end 108 of needle 100 significantly improves needle life, and its carbonization resistance.



FIG. 5 is a schematic illustration of an exemplary embodiment of an apparatus for laser assisted liposuction employing the illustrated embodiments, or other embodiments of the needle. Connector 116 connects needle 100 via an optical cable 156 to a source of laser radiation 160 configured to provide laser radiation emitted by one or more lasers incorporated in the source 160 to needle 100. Laser radiation source 160 may be packaged into a controller 164, or may be a stand alone unit. In some embodiments, needle 100 may be made long enough to connect directly to the source of laser radiation 160. In such cases, optical cable 156 may become redundant. Controller 164 may operate the source of laser radiation 160 in a pulse, continuous or other radiation mode.


Controller 164 may further include a facility 168 for adipose tissue laser treatment products removal and a display 172, and/or a set of buttons providing a user interface and synchronizing operation of said source of laser radiation 160 with facility 168. Controller 164 further includes a temperature feedback loop 176 configured to receive temperature from a temperature sensor (see FIG. 8) and adapt laser power such as to provide safe tissue treatment. When laser radiation of proper power and wavelength is applied to adipose tissue, it liquefies the tissue and, in particular, the fat. The liquefied adipose tissue may be removed or may be left in the body, where it gradually dissipates through the body. FIGS. 6A-C, collectively referred to as FIG. 6 is a schematic illustration of the third exemplary embodiment of a disposable laser radiation conveying needle with liquefied fat removal channels. FIG. 6A is a cross section of a disposable needle 600. Needle 600 has a type of jacket 180 implemented as a structure containing a number of liquid conducting channels 184. Jacket 180 may be connected to facility 168, which may be a stand-alone facility or incorporated into controller 164 facility for liquefied fat and other adipose tissue laser treatment products removal. Needle 600 includes a solid light conducting core 620, a cladding 624 having a refractive index lower than core 620. A suction or vacuum provided by a pump (not shown) that is a part of facility 168 removes the liquefied tissue. Optical cable 156 (FIG. 5) may be implemented to have liquid conducting channels 184 in addition to optical fiber or a liquid collecting chamber communicating with a separate liquid conducting channel included in cable 156.



FIG. 6B illustrates a flexible or rigid needle 186 having a hollow light guide 188. The open end of guide 188, which is introduced into the adipose tissue, is terminated by a sapphire, diamond, or YAG window 190. Similar to needle 600 of FIG. 6A, needle 186 has channels 184 for liquefied fat and other adipose tissue laser treatment products removal.



FIG. 6C is an illustration of a needle 202 the body 204 of which is made of sapphire. Such needle is more resistant than plastic or glass needles to deposition on it of carbonized laser treatment products. Needle 202 may have a jacket (not shown) with liquid conducting channels. Alternatively, the jacket may be made of porous material with a suitable degree of porosity.



FIG. 7 is a schematic illustration of the method of tissue treatment with the apparatus of various embodiments presented in the present disclosure, as well as embodiments not presented. For adipose tissue 210 treatment, needle 100, or any other needle described above or other needle embodiments incorporating one or more of the above-described elements, is connected by its second end 112 to a source of laser radiation 160 located in controller 164. First end 108 of needle 100 pierces the subject skin or tissue 210 and enables insertion of needle 100 into a target volume 218 of adipose tissue 210 to be treated. Controller 164 operates laser source 160 to irradiate target volume 218 of adipose tissue 210. Radiation provided by one or more laser sources 160 liquefies at least a section of adipose tissue 210 adjacent to the first end 108 of needle 100. Controller 164 operates adipose tissue laser treatment products removal facility 168 that removes liquefied fat simultaneously with laser source 160.


In order to facilitate the process of tissue melting location observation an additional, second laser, visible through skin/tissue laser, such as a HeNe laser may be coupled to the needle or cable 156. This second laser, which is visible through skin, may assist the treatment provider in repositioning first end 108 of needle 100. In an alternative embodiment, a temperature sensitive cream, or a temperature sensitive liquid crystal paste, or a liquid crystal film may be spread on the tissue over the treated adipose tissue section. The paste/cream and the film may be such as Chromazone ink commercially available from Liquid Crystal Resources/Hallcrest, Inc. Glenview Ill. 60026 U.S.A. Needle 100 may be disposed of upon completion of treatment.



FIG. 8 is a schematic illustration of a forth exemplary embodiment of a disposable laser radiation conveying needle. Needle 230 is similar to any one of earlier described needles or may incorporate one or more of the afore-described aspects. It connects to a handle 240 which, with the help of optical cable 244, connects to controller 164. A temperature sensor 248 is mounted on a cantilever 252 configured to follow the first end 256 of needle 230 and measure the temperature of the tissue surface 262. Sensor 248 measures the temperature on the surface of the skin/tissue, and indicates or cuts-off the laser power when the treatment should be discontinued to avoid damage to the tissue surface 262. Temperature sensor 248 may be a contact sensor, being in contact with skin 262 or a non-contact sensor. During the treatment, the treatment provider moves handle 240 back and forth, as shown by arrow 242 within tissue 264. Temperature sensor 248 follows laser radiation emitting first end 256 of needle 230 and provides tissue/skin 262 temperature reading to controller 164 controlling the laser power coupled to the treated tissue volume 260. A feedback loop 176 of controller 164 is configured to read the temperature sensor and adapt laser power such as to provide safe tissue treatment. Cantilever 252 with temperature sensor 248 attached to it may be implemented as a part of handle 240 or as a removable and disposable or reusable part.


As disclosed above, source of laser radiation 160 may contain one or more laser sources operating at the same or different wavelengths. Accordingly, in an additional embodiment, laser beams from two laser sources with different wavelengths could be used to optimize simultaneous adipose tissue (or fat) destruction and blood hemostatis. The laser wavelengths may be, for example, 1,064 micrometer wavelength provided by a NdYAG laser and a 0.9 micrometer wavelength provided by a laser diode. Another suitable set of wavelengths is 1,064 micron and 0.532 micron. Such combination of laser wavelengths reduces bleeding, makes the fat removal procedure safer and shortens the patient recovery time.


In yet a further embodiment, two lasers guided through the same needle may operate each in different modes of operation. For example, a continuous wave (CW) laser with wavelength of 0.808 micron, 0.980 micron or about 1,500 micron may be delivered to target volume 218 (FIG. 7) of adipose tissue to preheat the volume to a desired temperature and liquefy the adipose tissue (fat).


Following this or almost simultaneously with a CW operating laser that heats-up the tissue, a pulsed IR laser, for example an Ho—(Holmium), Tm—(Thulium) or Er:Yag (Erbium Yttrium Aluminum Garnet) laser generating pulses in sub-millisecond or millisecond range may be applied to the same target tissue volume 218. During the course of the laser pulse, the target tissue (cells and intercellular fluid) near the end 108 of needle 100 changes to overheated (high-pressure) gas forming expanding micro bubbles collapsing at the end of the pulse. Mechanical stress developed by the pulsed laser action can increase the rate of membrane of adipose cells disruption and release of liquefied fat from the cell. This opto-mechanical action of laser radiation makes fat removal/suction more efficient.



FIG. 9 is a schematic illustration of an additional embodiment of an apparatus for laser assisted liposuction employing one of the afore-described needles or other needle embodiments including one or more of the afore-described aspects or elements. Fiber optics type connector 116 (FIGS. 1, 4, and 5) may be implemented as a T-type connector 236 where fluid/liquid conducting channels 184 (FIG. 6A) connect directly to laser treatment products removal facility 168 via a tube 274. This element simplifies cable 156 structure so that the cable 156 contains a light guide only.


The apparatus disclosed above may also be used for skin tightening. The needle is inserted subcutaneously into a treatment recipient so that the first end of the fiber is introduced within the tissue underlying the dermis. Laser source emits radiation of suitable power that is conveyed by the needle to the dermis, where the radiation causes collagen destruction and shrinkage within the treatment area.


Advantageously, the described embodiments of disposable needles enable continuous adipose tissue treatment process eliminates, or at least provides great attenuation in, the need for frequent needle removal, cleaning, and cleaving. Further, this advantageously significantly reduces the treatment time, makes the subject treatment more comfortable and simplifies the treatment process.


While the exemplary embodiments of the disposable needle and the method of using it have been illustrated and described, it will be appreciated that various changes can be made therein without affecting the spirit and scope of the needle and the method of using it. The scope of the needle and the method of using it, therefore, are defined by reference to the following claims presented herein.

Claims
  • 1. A method for adipose tissue laser treatment, said method comprising: introducing into a target volume of adipose tissue a needle comprising a light conducting body having a first end being configured for introduction into adipose tissue and a second end, adapted to connect to a source of laser radiation including at least one laser operating in a continuous operation mode (CW) and at least one laser source operating in a pulse operation mode;causing the at least one laser in operating in continuous operation mode (CW) and the at least one laser source operating in a pulse operation mode to operate substantially simultaneously,wherein the laser operating in the continuous operation mode (CW) heats up the adipose tissue and the laser source operating in the pulse operation mode induces mechanical stress on the adipose tissue.
  • 2. The method according to claim 1, wherein the laser operating in the continuous operation mode (CW) and the laser source operating in the pulse operation are at least one of a group of lasers consisting of a Ho—(Holmium) laser, Tm—(Thulium) laser or Er:Yag (Erbium Yttrium Aluminum Garnet) laser.
  • 3. The method according to claim 1, wherein both laser sources affect the adipose tissue at the location being irradiated.
  • 4. The method according to claim 1, further comprising monitoring the temperature of the target volume of the adipose tissue and adjusting the at least one laser source to avoid excessive damage to the target volume of adipose tissue; and wherein monitoring of temperature is performed by a temperature sensor mounted on a cantilever configured to follow the first end of the needle and measure the temperature of the tissue surface.
  • 5. The method according to claim 1, further comprising operating simultaneously with one or more laser sources, a facility for adipose tissue laser removal.
  • 6. The method according to claim 1, wherein at least two laser sources with different wavelengths are utilized to reduce bleeding.
  • 7. The method according to claim 6, wherein the two lasers with different wavelengths are operating at a wavelength of 1,064 micrometers and a group of wavelengths consisting of a wavelength of 0.9 micrometers and a wavelength of 0.532 microns.
  • 8. A disposable needle for introduction into and treatment of adipose tissue through the application of laser energy, the disposable needle comprising: a light conducting body having a receiving end configured to connect at least to a multiple-source of laser radiation; andthe disposable needle being further configured to be removably coupled to two or more laser sources of the multiple-source of laser radiation, with at least one laser source operating in continuous (CW) operation mode and at least one laser source operating in pulse operation mode and the laser operating in continuous (CS) operation mode and the at least one laser source operating in pulse operation mode operating substantially simultaneously; andwherein the disposable needle is configured such that when introduced into an adipose tissue, the disposable needle delivers the laser operating in the continuous operation mode (CW) into the adipose tissue to cause the adipose tissue to be heated and the disposable needle delivers the laser source operating in the pulse operation mode such that mechanical stress is induced on the adipose tissue.
  • 9. A method for using the needle of claim 8, said method comprising: connecting said needle to at least one source of laser radiation and operating the source of laser radiation;introducing the needle into a target volume of adipose tissue; andsupplying laser radiation of sufficient power to convert at least a volume of the adipose tissue into a liquid.
  • 10. The disposable needle according to claim 8, further comprising a temperature sensor located over the treated tissue volume and configured to follow the first end of the needle and measure the temperature of the surface of the tissue over the affected tissue volume.
  • 11. The disposable needle according to claim 8, wherein the temperature sensor is one of a group of contact sensors or non-contact sensors.
  • 12. The disposable needle according to claim 8, wherein the temperature sensor provides the temperature reading to a controller that controls laser power coupled to the treated skin volume.
  • 13. The disposable needle according to claim 8, wherein: the laser that induces mechanical stress on the adipose tissue is at least one of a group of lasers consisting of a Ho—(Holmium) laser, Tm—(Thulium) laser or Er:Yag (Erbium Yttrium Aluminum Garnet); andthe laser generates pulses in sub-millisecond or millisecond range.
  • 14. The disposable needle according to claim 8, further comprising at least two lasers with one laser operating at a wavelength of 1,064 micrometer and a second laser operating at least at one of a group of wavelengths consisting of a wavelength of 0.9 micrometers and a wavelength of 0.532 microns.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a non-provisional application being filed under 37 CFR 1.53(b) and 35 USC 111 as a divisional of the presently pending U.S. patent application Ser. No. 12/357,564 filed on Jan. 22, 2009, which application claims priority to U.S. Provisional Application for Patents 61/023,194 filed on Jan. 24, 2008 and U.S. Provisional Application for Patents 61/085,424 filed on Aug. 1, 2008, all of which are hereby incorporated by reference.

US Referenced Citations (343)
Number Name Date Kind
2183726 Sommer et al. Feb 1939 A
2231095 Sommer et al. Feb 1941 A
2824308 Duncan Feb 1958 A
2888927 Fozard Jun 1959 A
3088205 Ellis May 1963 A
D196532 Facci Oct 1963 S
4174713 Mehl Nov 1979 A
4182329 Smit et al. Jan 1980 A
4185632 Shaw Jan 1980 A
4200104 Harris Apr 1980 A
4211230 Woltosz Jul 1980 A
4321926 Roge Mar 1982 A
D269294 Rakocy et al. Jun 1983 S
D271015 Geraets Oct 1983 S
D271199 Geraets Nov 1983 S
D274462 Rakocy et al. Jun 1984 S
4532924 Auth et al. Aug 1985 A
4550728 Runyon et al. Nov 1985 A
4553936 Wang Nov 1985 A
4566454 Mehl et al. Jan 1986 A
4753958 Weinstein et al. Jun 1988 A
4784135 Blum et al. Nov 1988 A
4844063 Clark Jul 1989 A
4867682 Hammesfahr et al. Sep 1989 A
4869584 Dion Sep 1989 A
4940456 Sibalis et al. Jul 1990 A
4979180 Muncheryan Dec 1990 A
5016999 Williams May 1991 A
5087240 Sibalis Feb 1992 A
5125928 Parins et al. Jun 1992 A
5158537 Haak et al. Oct 1992 A
5169384 Bosniak et al. Dec 1992 A
5250023 Lee et al. Oct 1993 A
5286479 Garlich et al. Feb 1994 A
5316473 Hare May 1994 A
5348554 Imran et al. Sep 1994 A
5383874 Jackson et al. Jan 1995 A
5402697 Brooks Apr 1995 A
5406340 Hoff Apr 1995 A
5418130 Platz et al. May 1995 A
5487662 Kipke et al. Jan 1996 A
5509916 Taylor Apr 1996 A
5520684 Imran May 1996 A
5521392 Kennedy et al. May 1996 A
5582476 Hansen Dec 1996 A
5611793 Wilson et al. Mar 1997 A
5642997 Gregg et al. Jul 1997 A
5658148 Neuberger et al. Aug 1997 A
5674191 Edwards et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5683380 Eckhouse et al. Nov 1997 A
5693052 Weaver Dec 1997 A
5698866 Doiron et al. Dec 1997 A
5704935 Pahl et al. Jan 1998 A
5707403 Grove et al. Jan 1998 A
5718702 Edwards Feb 1998 A
5722411 Suzuki et al. Mar 1998 A
5735844 Anderson et al. Apr 1998 A
5769880 Truckai et al. Jun 1998 A
5776092 Farin et al. Jul 1998 A
5814008 Chen et al. Sep 1998 A
5824023 Anderson Oct 1998 A
5846252 Mehl, Sr. Dec 1998 A
5868744 Willmen Feb 1999 A
5871469 Eggers et al. Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5888198 Eggers et al. Mar 1999 A
5935143 Hood Aug 1999 A
5949514 Wargon Sep 1999 A
5954710 Paolini et al. Sep 1999 A
5961482 Chien et al. Oct 1999 A
5983130 Phipps et al. Nov 1999 A
5983135 Avrahami Nov 1999 A
5984915 Loeb et al. Nov 1999 A
5993180 Westerhof et al. Nov 1999 A
6024733 Eggers et al. Feb 2000 A
6030384 Nezhat Feb 2000 A
6042959 Debe et al. Mar 2000 A
6056548 Neuberger et al. May 2000 A
6063108 Salansky et al. May 2000 A
6066134 Eggers et al. May 2000 A
6078830 Levin et al. Jun 2000 A
6080127 Li et al. Jun 2000 A
6080391 Tsuchiya et al. Jun 2000 A
6081934 Stefanovsky et al. Jul 2000 A
6097976 Yang et al. Aug 2000 A
6107326 Jori Aug 2000 A
6132701 Perez et al. Oct 2000 A
6148232 Avrahami Nov 2000 A
6159222 Yiu Dec 2000 A
6173202 Eppstein Jan 2001 B1
6187001 Azar et al. Feb 2001 B1
6190609 Chapman et al. Feb 2001 B1
6191110 Jaynes et al. Feb 2001 B1
6208881 Champeau Mar 2001 B1
6210402 Olsen et al. Apr 2001 B1
6221095 Van Zuylen et al. Apr 2001 B1
6231571 Ellman et al. May 2001 B1
6231593 Meserol May 2001 B1
6251127 Biel Jun 2001 B1
6256525 Yang et al. Jul 2001 B1
6258319 Hearst et al. Jul 2001 B1
6273884 Altshuler et al. Aug 2001 B1
6275728 Venkatraman Aug 2001 B1
6277116 Utely et al. Aug 2001 B1
6280438 Eckhouse et al. Aug 2001 B1
6288498 Cheng Sep 2001 B1
6302874 Zhang et al. Oct 2001 B1
6308413 Westerhof et al. Oct 2001 B1
6325797 Stewart et al. Dec 2001 B1
6343400 Massholder et al. Feb 2002 B1
6343933 Montgomery et al. Feb 2002 B1
6374653 Gokcebay et al. Apr 2002 B1
6400976 Champeau Jun 2002 B1
6406157 Audet Jun 2002 B1
6413255 Stern Jul 2002 B1
6419674 Bowser et al. Jul 2002 B1
6433343 Cimino et al. Aug 2002 B1
6440121 Weber et al. Aug 2002 B1
6461354 Olsen et al. Oct 2002 B1
6461567 Hearst et al. Oct 2002 B1
6462070 Hasan et al. Oct 2002 B1
6471716 Pecukonis Oct 2002 B1
6477410 Henley et al. Nov 2002 B1
6482201 Olsen et al. Nov 2002 B1
6482204 Lax et al. Nov 2002 B1
6487447 Weimann et al. Nov 2002 B1
6490482 Mori et al. Dec 2002 B2
6493940 Westerhof et al. Dec 2002 B2
6494900 Salansky et al. Dec 2002 B1
6497702 Bernaz Dec 2002 B1
6508813 Altshuler Jan 2003 B1
6510341 Kuribayashi et al. Jan 2003 B1
6511475 Altshuler et al. Jan 2003 B1
6514243 Eckhouse et al. Feb 2003 B1
6514248 Eggers et al. Feb 2003 B1
6517532 Altshuler et al. Feb 2003 B1
6533775 Rizoiu Mar 2003 B1
6544259 Tsaliovich Apr 2003 B1
6544261 Ellsberry et al. Apr 2003 B2
6558653 Andersen et al. May 2003 B2
6572637 Yamazaki et al. Jun 2003 B1
6582429 Krishnan et al. Jun 2003 B2
6594905 Furst et al. Jul 2003 B2
6595947 Mikszta et al. Jul 2003 B1
6595990 Weinstein et al. Jul 2003 B1
6597946 Avrahami et al. Jul 2003 B2
6602245 Thiberg Aug 2003 B1
6611706 Avrahami et al. Aug 2003 B2
6611707 Prausnitz et al. Aug 2003 B1
6612819 Furst et al. Sep 2003 B1
6615079 Avrahami Sep 2003 B1
6618620 Freundlich et al. Sep 2003 B1
6620158 Ronci Sep 2003 B2
6623454 Eggers et al. Sep 2003 B1
6629974 Penny et al. Oct 2003 B2
6632002 Chubb et al. Oct 2003 B1
6632193 Davison et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6637877 Hartley et al. Oct 2003 B1
6659106 Hovda et al. Dec 2003 B1
6663620 Altshuler et al. Dec 2003 B2
6676655 McDaniel Jan 2004 B2
6678554 Sun et al. Jan 2004 B1
6702808 Kreindel Mar 2004 B1
6708060 Avrahami et al. Mar 2004 B1
6711435 Avrahami Mar 2004 B2
6719754 Underwood et al. Apr 2004 B2
6723092 Brown et al. Apr 2004 B2
D490156 Fischer et al. May 2004 S
D490526 Jonsen May 2004 S
6740079 Eggers et al. May 2004 B1
6743211 Prausnitz et al. Jun 2004 B1
6758845 Weckwerth et al. Jul 2004 B1
6761729 Babaev Jul 2004 B2
6767341 Cho Jul 2004 B2
6770069 Hobart et al. Aug 2004 B1
6773431 Eggers et al. Aug 2004 B2
6780838 Lipton et al. Aug 2004 B2
RE38643 Sugaya et al. Nov 2004 E
6887260 McDaniel May 2005 B1
6905496 Ellman et al. Jun 2005 B1
6974450 Weber et al. Dec 2005 B2
7006874 Knowlton et al. Feb 2006 B2
7022121 Stern et al. Apr 2006 B2
7077840 Altshuler et al. Jul 2006 B2
7115123 Knowlton et al. Oct 2006 B2
7118563 Weckwerth et al. Oct 2006 B2
7141049 Stern et al. Nov 2006 B2
7153298 Cohen Dec 2006 B1
7234239 Saito et al. Jun 2007 B2
7238183 Kreindel Jul 2007 B2
7251531 Mosher et al. Jul 2007 B2
7275819 Bleau Oct 2007 B2
7278993 Kelly et al. Oct 2007 B2
7435247 Woloszko et al. Oct 2008 B2
7494488 Weber Feb 2009 B2
7517344 Van Hal et al. Apr 2009 B2
7643874 Nitzan et al. Jan 2010 B2
7713266 Elkins et al. May 2010 B2
7771419 Carmel et al. Aug 2010 B2
7824394 Manstein Nov 2010 B2
7935107 Altshuler et al. May 2011 B2
8021360 Dunning et al. Sep 2011 B2
8034052 Podhajsky Oct 2011 B2
8109927 Kelly et al. Feb 2012 B2
8128622 Podhajsky et al. Mar 2012 B2
8133191 Rosenberg et al. Mar 2012 B2
8133216 Knopp et al. Mar 2012 B2
8157807 Ferren et al. Apr 2012 B2
8202268 Wells et al. Jun 2012 B1
8206381 Lischinsky et al. Jun 2012 B2
8235989 Palanker et al. Aug 2012 B2
8273037 Kreindel et al. Sep 2012 B2
8292882 Danek et al. Oct 2012 B2
8506564 Long et al. Aug 2013 B2
20010007068 Ota et al. Jul 2001 A1
20010014819 Ingle et al. Aug 2001 A1
20020010414 Coston et al. Jan 2002 A1
20020035363 Edwards et al. Mar 2002 A1
20020058936 Avrahami et al. May 2002 A1
20020082543 Park et al. Jun 2002 A1
20020104543 Hollander et al. Aug 2002 A1
20020120256 Furuno et al. Aug 2002 A1
20020120260 Morris et al. Aug 2002 A1
20020120261 Morris et al. Aug 2002 A1
20020128641 Underwood et al. Sep 2002 A1
20020128648 Weber et al. Sep 2002 A1
20020161324 Henley et al. Oct 2002 A1
20020173780 Altshuler et al. Nov 2002 A1
20020183245 Hasan et al. Dec 2002 A1
20020190337 House et al. Dec 2002 A1
20020193729 Cormier et al. Dec 2002 A1
20020198575 Sullivan Dec 2002 A1
20030004499 McDaniel Jan 2003 A1
20030018255 Martin et al. Jan 2003 A1
20030032950 Altshuler et al. Feb 2003 A1
20030055413 Altshuler et al. Mar 2003 A1
20030055414 Altshuler et al. Mar 2003 A1
20030109871 Johnson et al. Jun 2003 A1
20030185255 Ye et al. Oct 2003 A1
20030195494 Altshuler et al. Oct 2003 A1
20030199863 Swanson et al. Oct 2003 A1
20030199946 Gutwein Oct 2003 A1
20040010250 Manna et al. Jan 2004 A1
20040010298 Altshuler et al. Jan 2004 A1
20040015161 Lovewell Jan 2004 A1
20040015162 McGaffigan Jan 2004 A1
20040064167 Berry et al. Apr 2004 A1
20040133251 Altshuler et al. Jul 2004 A1
20040138603 Cleary et al. Jul 2004 A1
20040143308 Lundahl Jul 2004 A1
20040167501 Island et al. Aug 2004 A1
20040181216 Kelly et al. Sep 2004 A1
20040193234 Butler Sep 2004 A1
20040210214 Knowlton Oct 2004 A1
20040236320 Protsenko et al. Nov 2004 A1
20040260210 Ella et al. Dec 2004 A1
20040267252 Washington et al. Dec 2004 A1
20050015042 Sun et al. Jan 2005 A1
20050033286 Eggers et al. Feb 2005 A1
20050043653 Trimmer et al. Feb 2005 A1
20050049543 Anderson et al. Mar 2005 A1
20050085804 McGaffigan Apr 2005 A1
20050096646 Wellman et al. May 2005 A1
20050137654 Hoenig et al. Jun 2005 A1
20050137655 MacFarland et al. Jun 2005 A1
20050147137 Slatkine Jul 2005 A1
20050149012 Penny et al. Jul 2005 A1
20050177139 Yamazaki et al. Aug 2005 A1
20050288680 Ingle et al. Dec 2005 A1
20060036300 Kreindel Feb 2006 A1
20060058712 Altshuler et al. Mar 2006 A1
20060130675 Crawford Jun 2006 A1
20060200213 McDaniel Sep 2006 A1
20060224148 Cho et al. Oct 2006 A1
20060231568 Lynn et al. Oct 2006 A1
20060247741 Hsu et al. Nov 2006 A1
20060253112 Suarez et al. Nov 2006 A1
20060271028 Altshuler et al. Nov 2006 A1
20070009542 Levin et al. Jan 2007 A1
20070016117 Sliwa et al. Jan 2007 A1
20070038206 Altshuler et al. Feb 2007 A1
20070093798 Debenedictis et al. Apr 2007 A1
20070106349 Karni et al. May 2007 A1
20070129711 Altshuler et al. Jun 2007 A1
20070142881 Hennings Jun 2007 A1
20070191821 Boxer Wachler Aug 2007 A1
20070191827 Lischinsky et al. Aug 2007 A1
20070197895 Nycz et al. Aug 2007 A1
20070198004 Altshuler et al. Aug 2007 A1
20070213696 Altshuler et al. Sep 2007 A1
20070239142 Altshuler et al. Oct 2007 A1
20070239143 Altshuler et al. Oct 2007 A1
20070239152 Trezon Oct 2007 A1
20070264626 DeBenedictis et al. Nov 2007 A1
20070271714 Adam et al. Nov 2007 A1
20070293849 Hennings et al. Dec 2007 A1
20080004678 Kreindel Jan 2008 A1
20080123238 Campos et al. May 2008 A1
20080139974 Da Silva Jun 2008 A1
20080183167 Britva et al. Jul 2008 A1
20080188846 Palanker et al. Aug 2008 A1
20080200910 Burger et al. Aug 2008 A1
20080214986 Ivorra et al. Sep 2008 A1
20080214988 Altshuler et al. Sep 2008 A1
20080215124 Wagenaar et al. Sep 2008 A1
20080221504 Aghion Sep 2008 A1
20080274166 Sacks et al. Nov 2008 A1
20080294153 Allshuler et al. Nov 2008 A1
20080306476 Hennings et al. Dec 2008 A1
20090036953 Gustavsson Feb 2009 A1
20090043293 Pankratov et al. Feb 2009 A1
20090105706 Livneh Apr 2009 A1
20090112205 McGill et al. Apr 2009 A1
20090171341 Pope et al. Jul 2009 A1
20090182315 Zigan et al. Jul 2009 A1
20090192503 Epshtein et al. Jul 2009 A1
20090222023 Boone et al. Sep 2009 A1
20090234341 Roth Sep 2009 A1
20090234342 Ely et al. Sep 2009 A1
20090299361 Flyash et al. Dec 2009 A1
20100010480 Mehta et al. Jan 2010 A1
20100145321 Altshuler et al. Jun 2010 A1
20100185193 Kreindel Jul 2010 A1
20100198134 Eckhouse Aug 2010 A1
20100211055 Eckhouse et al. Aug 2010 A1
20100249772 Mehta et al. Sep 2010 A1
20110015549 Eckhouse et al. Jan 2011 A1
20110160712 Tankovich et al. Jun 2011 A1
20110166559 Eckhouse et al. Jul 2011 A1
20110196363 Kreindel Aug 2011 A1
20120016354 Epshtein et al. Jan 2012 A9
20120022435 Ignon et al. Jan 2012 A1
20120022504 Epshtein et al. Jan 2012 A1
20120022512 Vaynberg Jan 2012 A1
20120022518 Levinson Jan 2012 A1
20120123397 Epshtein et al. May 2012 A1
20120143178 Mehta Jun 2012 A9
20120197242 Rosenberg Aug 2012 A1
20120290023 Boyden et al. Nov 2012 A1
20130144280 Eckhouse et al. Jun 2013 A1
20130289679 Eckhouse et al. Oct 2013 A1
Foreign Referenced Citations (15)
Number Date Country
2495005 Feb 2004 CA
1078383 Nov 1993 CN
0743029 Jul 2002 EP
0824019 Nov 2002 EP
2125986 Aug 1982 GB
2202442 Sep 1988 GB
04299998 Oct 1992 JP
06113920 Apr 1994 JP
11132843 Dec 1999 JP
2003034630 Feb 2003 JP
WO-9321992 Nov 1993 WO
WO-9909143 Feb 1999 WO
WO-02078644 Oct 2002 WO
WO-03039367 May 2003 WO
WO 2007137304 Nov 2007 WO
Non-Patent Literature Citations (52)
Entry
Acne Clearance, LHE Clinical Casebook, Radiancy: Lighting the Future of Skin Care, © 2002.
Acne Star web page, describing “How to use get rid of Acne Treatment”, printed May 5, 2005.
Acne Star web page, describing Clinical Studies, “The Treatment of acne vulgaris with a novel device that uses Gallium—Nitride diode light”, printed May 5, 2005.
Aesthetic Buyers Guide: The Leading Cosmetic Practice Resource, Jan./Feb. 2004, vol. 7, No. I.
Bollen, CM. et al., “Full- versus partial-mouth disinfection in the treatment of periodontal infections. A pilot study: long-term microbiological observations”, J Clin Periodontol Oct. 1996;23(10):960-70 (Abstract).
Bollen, CM. et al., “The effect of a one-stage full-mouth disinfection on different intra-oral niches. Clinical and microbiological observations”, J Clin Periodontol Jan. 1998;25(1 ):56-66 (Abstract).
Calderi-Iead, R. Glen, “The Photobiology of LED Phototherapy”.
Charakida et al., “Phototherapy in the Treatment of Acne Vulgaris, What is the Role?”, Am. J. Clin. Dermatol 2004: 5(4): 211-216.
Cohen LR., “What causes bad breath?”, University of Toronto; webpage (printed before Nov. 2, 2004).
Coventry et al. (2000) “ABC of oral health: Periodontal disease” British Medical Journal, 321, 36-39.
De Soete, M. et al., “One-stage full-mouth disinfection. Long-term microbiological results analyzed by checker board DNA-DNA hybridization”, J Periodontol Mar. 2001; 72(3):374-82 (Abstract).
Elman M. et al., “The effective treatment of acne vulgaris by a high-intensity, narrow bank 405-420 nm light source”, Cosmetic & Laser Ther 2003; 5: 111-116.
Flow Control Network web page, “Mini Diaphragm Pumps for Precision Dispensing” by Ping Lin, printed Aug. 2, 2005.
Friedberg JS et al., “Antibody-Targeted Photolysis Bacteriocidal Effects of Sn (IV) Chlonn e6-Dextran-Monoclonal Antibody Conjugates”, Annals New York Academy of Sciences 618:383-393, 1991.
Greenstein G., Full-mouth therapy versus individual quadrant root planning: a critical commentary, JPeriodontol Jul. 2002;73(7):797-812 (Abstract).
Hamblin, M. et al., “Rapid Control of Wound Infections by Targeted Photodynamic Therapy Monitored by In Vivo Bioluminescence Imagining”, Photochemistry and Photobiology, 2002, 75(1 ); 51-57.
Komerik et al. (2003) “In vivo killing of Porphyromonas gingivalis by toluidine blue-mediated Photosensitization in an animal model” Antimicrobial Agents and Chemotherapy, 47(3), 932-940.
Krespi, et al. (2005) “Lethal photosensitization of oral pathogens via red-filtered halogen larnp” Oral Diseases, 11(S1 ), 92-95.
Malik, Z. et al., “New Trends in Photobiology (Invited Review) Bactericidal Effects of Photoactivated Porphyrins—An Alternative Approach to Antimicrobial Drugs”, Journal of Photochemistry and Photobiology, B: Biology, 5—1—1990}—281-293.
Matevski D. et al., “Lethal photosensitization of periodontal pathogens by a red-filtered Xenon lamp in invitro”, JPeriodont. Res. 2003. 38:428-435.
Matevski D. et al., “Sensitivity of Porphyromonas gingivalis to Light-Activated Toluidine Blue O”, University of Toronto, Faculty of Dentistry; Slide presentation (presented before Nov. 15, 2002).
Meisel etal. (2005) “Photodynamic therapy for periodontal diseases: State of the are” J. Photochem. Photobiol., 79, 159-170.
Mongardini, C. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized early-onset periodontitis. I. Long-term clinical observations”, J Periodontol Jun. 1999;70(6):632-45 1Abstrac!2.—.
Morton C.A. et al., An open study to determine the efficacy of blue light in the treatment of mild to moderate ance: preliminary data (publication status unknown).
Nakano et al. (2002) “Correlation between oral malodor and periodontal bacteria” Microbes Infect., 4(6), 679-683.
Ondine Biopharma web page—printed Oct. 15, 2002.
Papageorgiou et al., “Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris”, British Journal of Dermatology 2000: 142: 973-978.
Pharmaceutical description, Levulan® Kerastick *arninolevulinic acid I-IC!) for Topical Solution, 20′X.
Quirynen, M. et al. “Full- vs. partial-mouth disinfection in the treatment of periodontal infections: short-term clinical and microbiological observations”, J Dent Res Aug. 1995;74(8):1459-67 (Abstract).
Quirynen, M. et al., “The effect of a 1-stage full-mouth disinfection on oral malodor and microbial colonization of the tongue in periodontitis. A pilot study”, J Periodontol Mar. 1998;69(3):374-82 (Abstract).
Quirynen, M. et al., “The intra-oral translocation of periodontopathogens jeopardises the outcome of periodontal therapy”, Journal of Clincial Periodontology, Jun. 2001, vol. 28, Issue 6, p. 499 (Abstract).
Quirynen, M. et al., “The role of chlorhexidine in the one-stage full-mouth disinfection treatment of patients with advanced adult periodontitis. Long-term clinical and microbiological observations”, J Clin Periodontol 2000 A1!JL2˜579-89 J—Abstrac—!).
Quirynen. M. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized early-onset periodontitis. II. Long-term impact on microbial load”, J Periodontol Jun. 1999;70(6):645-56 J—Abstrac!2.—.
Sanz et al. (2001) “Fundamentals of breath malodour” Journal of Contemporary Dental Practice, 2(4), 1-13.
Sarkar et al. (1993) “Lethal photosensitization of bacteria in subgingival plaque from patients with chronic periodontitis”J. Periodont. Res , 28, 204-21 O.
Skin91 I .corn web page regarding Peter Thomas Roth Clinical Acne Medication, acne treatment-Benzoyl Peroxide 5% pbp5, printed Apr. 19, 2005.
Soukos et al. (1998) “Targeted antimicrobial photochemotherapy”, Antimicrobial Agents and Chemotherapy 42 ( 10 ), 2595-2601.
Spire Awarded Contract for Ear Surgery Laser—Press Release Aug. 23, 2002.
Temperatures.corn web page, “Thermistor Temperature Sensors,” printed Aug. 2, 200.
Vandekerckhove, BN. et al.. “Full- versus partial-mouth disinfection in the treatment of periodontal infections. Long-term clinical observations of a pilot study”, J Periodontol Dec. 1996;67(12):1251-9 (Abstract).
Wainwright M., Photodynamic antimicrobial chemotherapy (PACT), Journal of Antimicrobial Chemotherapy (1998) 42, 13-28.
Wilson (2005) “Lethal photosensitisation of oral bacteria and its potential application in the photodynamic therapy of oral infection” Photochem. Photobiol. Sci., 3, 412-418.
Wilson et al. (1995) “Bacteria in supragingival plaque samples can be killed by low-power laser light in the presence of a photosensitizer” J. Appl. Bacteriol., 78, 569-574.
Wood, et al. (1999) “An in vitro study of the use of photodynamic therapy for the treatment of natural oral plaque biofilrms formed in vivo” J. Photochem. Photogiol. B: Biol., 50, 1-7.
www.lightbioscience.com web page, Gentle Waves Cosmcceuticals, printed Jul. 29, 200.
www.lightbioscience.com web page, Gentle Waves LED Photomodulation Fact Sheet, printed Jul. 29, 2005.
PCT/IL08/01612 International Search Report.
PCT/IL09/00695 International Search Report.
PCT/IL09/00817 International Search Report.
PCT/IL09/00856 International Search Report.
PCT/IL10/00222 International Search Report.
PCT/IL2010/001025 International Search Report.
Related Publications (1)
Number Date Country
20140031803 A1 Jan 2014 US
Provisional Applications (2)
Number Date Country
61023194 Jan 2008 US
61085424 Aug 2008 US
Divisions (1)
Number Date Country
Parent 12357564 Jan 2009 US
Child 14041185 US